BCL2L11 Human shRNA Plasmid Kit (Locus ID 10018)
BCL2L11 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector
|Product Name||BCL2L11 Human shRNA Plasmid Kit (Locus ID 10018)|
|Synonyms||BAM; BIM; BOD|
|Kit Components||BCL2L11 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 10018). 5µg purified plasmid DNA per constructNon-effective 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.|
|RefSeq||NM_001204106, NM_001204107, NM_001204108, NM_001204109, NM_001204110, NM_001204111, NM_001204112, NM_001204113, NM_006538, NM_138621, NM_138622, NM_138623, NM_138624, NM_138625, NM_138626, NM_138627, NM_207002, NM_207003, XM_005263550, XM_005263551, XM_005263552, XM_005263553, XM_005263554, XM_005263555, XM_005263556, XM_005263557, XM_005263559, XM_005263561, XM_011510461, XM_011510464, XM_017003101, XM_017003102, XR_001738579, XR_001738580, XR_244801, XR_922828, XR_922829|
|Summary||The protein encoded by this gene belongs to the BCL-2 protein family. BCL-2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. The protein encoded by this gene contains a Bcl-2 homology domain 3 (BH3). It has been shown to interact with other members of the BCL-2 protein family and to act as an apoptotic activator. The expression of this gene can be induced by nerve growth factor (NGF), as well as by the forkhead transcription factor FKHR-L1, which suggests a role of this gene in neuronal and lymphocyte apoptosis. Transgenic studies of the mouse counterpart suggested that this gene functions as an essential initiator of apoptosis in thymocyte-negative selection. Several alternatively spliced transcript variants of this gene have been identified. [provided by RefSeq, Jun 2013].|
|shRNA Design||These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service|
|Performance Guaranteed||OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
|The use of this RNAi has been cited in the following citations:|
RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy
,Luan, Q;Jin, L;Jiang, CC;Tay, KH;Lai, F;Liu, XY;Liu, YL;Guo, ST;Li, CY;Yan, XG;Tseng, HY;Zhang, XD;,
Autophagy May 2015,PubMed ID 26018731